Literature DB >> 22750064

Diacerein decreases visceral pain through inhibition of glutamatergic neurotransmission and cytokine signaling in mice.

Vinícius Maria Gadotti1, Daniel Fernandes Martins, Heyde Francine Pinto, Gabrielle Oliveira, Manuella Pinto Kaster, Nara Lins M Quintão, Adair Roberto Soares Santos.   

Abstract

The present study evaluated the antinociceptive effect of the pro-inflammatory cytokines inhibitor diacerein in mice and its possible mechanism of action. The antinociception produced by diacerein was tested at different sites of action, moreover selective antagonists or agonists were used to identify the mechanism that may be involved in its antinociceptive action against acetic acid-induced visceral pain. Diacerein administered systemically (intraperitoneal [i.p.] or intra-gastric [i.g.] routes), supra-spinally (i.c.v.), spinally (i.t.) or peripherally (in association with the irritant agent) inhibited the visceral nociception induced by acetic acid in mice. Interestingly, diacerein treatment (25 mg/kg, i.p. or 50 mg/kg, i.g.) produced long-lasting (for up to 4 h) inhibition of acetic acid-induced nociception. Intraperitoneal treatment of mice with diacerein (25.0 mg/kg) inhibited somatic nociception induced by i.t. injection of glutamate, NMDA, kainate, and trans-ACPD but not that caused by AMPA. Diacerein (5.0-25.0 mg/kg) also produced dose related inhibition of interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) induced nociception. These results indicate that diacerein produces antinociception by inhibiting glutamatergic transmission through both ionotropic and metabotropic receptors as well as activity of pro-inflammatory cytokines.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750064     DOI: 10.1016/j.pbb.2012.06.018

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Diacerein, an inhibitor of IL-1β downstream mediated apoptosis, improves radioimmunotherapy in a mouse model of Burkitt's lymphoma.

Authors:  Javeria Zaheer; A Ram Yu; Hyeongi Kim; Hyun Ji Kang; Min Kyoung Kang; Jae Jun Lee; Jin Su Kim
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).

Authors:  Win Min Oo; David J Hunter
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-20       Impact factor: 3.625

Review 3.  Preclinical Assessment of Inflammatory Pain.

Authors:  Milind M Muley; Eugene Krustev; Jason J McDougall
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

4.  Visceral pain and gastrointestinal microbiome.

Authors:  Maciej Chichlowski; Colin Rudolph
Journal:  J Neurogastroenterol Motil       Date:  2015-03-30       Impact factor: 4.924

5.  Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats.

Authors:  Marwa M M Refaie; Entesar F Amin; Nashwa F El-Tahawy; Aly M Abdelrahman
Journal:  J Toxicol       Date:  2016-01-20

6.  Identification of interleukin-1 beta as a key mediator in the upregulation of Cav3.2-USP5 interactions in the pain pathway.

Authors:  Patrick L Stemkowski; Agustin Garcia-Caballero; Vinicius M Gadotti; Said M'Dahoma; Lina Chen; Ivana A Souza; Gerald W Zamponi
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

7.  Ulinastatin Exhibits Antinociception in Rat Models of Acute Somatic and Visceral Pain Through Inhibiting the Local and Central Inflammation.

Authors:  Mei-Xiang Zhan; Li Tang; Yun-Fei Lu; Huang-Hui Wu; Yi-Qing Zou; Zhi-Bin Guo; Zhong-Mou Shi; Chen-Long Yang; Fei Yang; Guo-Zhong Chen
Journal:  J Pain Res       Date:  2021-05-04       Impact factor: 3.133

Review 8.  Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment.

Authors:  Alicja Nowaczyk; Dawid Szwedowski; Ignacio Dallo; Jacek Nowaczyk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

9.  Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model.

Authors:  Raghda T Abdel-Latif; Walaa Wadie; Yousra Abdel-Mottaleb; Dalaal M Abdallah; Nabila N El-Maraghy; Hanan S El-Abhar
Journal:  Saudi Pharm J       Date:  2021-12-31       Impact factor: 4.330

10.  Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.

Authors:  R Bharti; G Dey; P K Ojha; S Rajput; S K Jaganathan; R Sen; M Mandal
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.